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Genetic Analyses of the Chimeric CYP11B1/CYP11B2 Gene in 
a Korean Family with Glucocorticoid-Remediable Aldosteronism
Glucocorticoid-remediable aldosteronism (GRA) is an autosomal-dominant inheritable 
form of hyperaldosteronism with early onset hypertension. GRA is caused by unequal 
crossing-over of the steroid 11β-hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) 
genes. As a result of chimeric gene duplication, aldosterone is ectopically synthesized in the 
adrenal zona fasciculata under the control of adrenocorticotropin. Here, we describe three 
cases of GRA in a Korean family. The proband-a 21-yr-old female-was incidentally found to 
have high blood pressure (170/108 mmHg). Her 46-yr-old father had been treated twice 
for cerebral hemorrhage at the ages of 29 and 39 yr. Her 15-yr-old brother had a 2-yr 
history of hypertension; however, he was never treated. Their laboratory test results showed 
normokalemia, hyporeninemia, hyperaldosteronism, and a high plasma aldosterone 
concentration-to-plasma renin activity ratio. Normal saline loading failed to suppress 
aldosterone secretion. However, dexamethasone administration effectively suppressed their 
plasma aldosterone concentrations. Following genetic analyses with PCR and direct 
sequencing to document the chimeric gene and crossover site, respectively, we identified 
CYP11B1/CYP11B2 and determined the breakpoint of unequal crossover to be located 
between intron 2 of CYP11B1 and exon 3 of CYP11B2. 
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INTRODUCTION
Glucocorticoid-remediable aldosteronism (GRA) is an autoso-
mal-dominant form of familial hyperaldosteronism associated 
with a high incidence of subarachnoid hemorrhages (1). This 
type of hyperaldosteronism results from unequal crossover of 
the genes encoding steroid 11β-hydroxylase (CYP11B1) and   
aldosterone synthase (CYP11B2). The regulatory sequence of 
CYP11B1 and the coding sequence of CYP11B2 constitute chi-
meric gene CYP11B1/CYP11B2 (2). Therefore, the aldosterone 
synthase activity of CYP11B1/CYP11B2 is regulated by adreno-
corticotropic hormone (ACTH) rather than the renin–angioten-
sin system. Normally, aldosterone synthase is expressed only in 
the adrenal glomerulosa, but this ACTH-responsive chimeric 
gene is ectopically expressed in the adrenal zona fasciculata, 
resulting in the production of aldosterone synthase and hybrid 
steroids such 18-oxosteroid and 18-hydroxysteroid (3). 
  The diagnosis of GRA is clinically important because it is treat-
ed specifically by suppressing ACTH with a synthetic glucocor-
ticoid such as prednisolone. Although the diagnosis is support-
ed by the dexamethasone suppression test, this test shows posi-
tive results for the other forms of familial hyperaldosteronism 
as well (4). Instead, a definitive diagnosis can be made by iden-
tifying the chimeric CYP11B1/CYP11B2 gene with either South-
ern blotting (2) or PCR (5). 
  In this report, we describe three cases of GRA in a Korean 
family. We performed genetic analyses by using PCR and direct 
sequencing to document the chimeric gene and crossover site, 
respectively. 
CASE REPORT
A 21-yr-old female was referred to our clinics for further evalua-
tion of thyroid incidentaloma in March 2009. On physical exam-
ination, her thyroid gland showed no positive findings, but her 
blood pressure was 170/108 mmHg. On studying the family his-
tory, we found that her father, aged 46 yr, had been treated twice 
for cerebral hemorrhage at the ages of 29 and 39 yr. Furthermore, 
her 15-yr-old brother also had a 2-yr history of hypertension but 
was never treated (Fig. 1). On laboratory workup, her routine 
laboratory and thyroid function tests were normal. Following 
ultrasound-guided fine-needle aspiration cytology for the 9- 
mm-sized thyroid incidentaloma, which showed hypoecho-
genicity, a diagnosis of adenomatous goiter was made. Under Lee IS, et al.  •  Genetic Analyses of GRA 
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the impression of secondary hypertension, additional laborato-
ry workup was conducted, showing the following results: plas-
ma aldosterone concentration (PAC), 24.8 ng/dL (1–16 ng/dL); 
plasma renin activity (PRA), 0.45 ng/mL/h (0.20–2.70 ng/mL/
h); PAC/PRA ratio, 55.1; sodium, 140 mEq/L (135–153 mEq/L); 
potassium, 4.0 mEq/L (3.5–5.3 mEq/L). To confirm hyperaldo-
steronism, normal saline loading was performed, but her PAC 
was not suppressed from 55.6 ng/dL to 52.6 ng/dL (Fig. 2A). Ad-
HTN
HTN
HTN
Fig. 1. The pedigree of the family showed with 
the proband indicated by black symbol. 
Circles, females; squares, males; HTN, hyperten­
sion. 
Fig. 2. Change of plasma renin activity (PRA) and plasma aldosterone concentration before and after normal saline loading test and dexamethasone suppression test. (A) 
Plasma renin activity (PRA) and plasma aldosterone concentration of proband before and after normal saline loading test. (B) Plasma renin activity (PRA), plasma aldosterone 
concentration and plasma cortisol of proband before and after dexamethasone suppression test. (C) Plasma renin activity (PRA) and plasma aldosterone concentration of younger 
brother of proband before and after normal saline loading test. (D) Plasma renin activity (PRA), plasma aldosterone concentration and plasma cortisol of younger brother of 
proband before and after dexamethasone suppression test. 
Squares, plasma aldosterone concentration; triangle, plasma renin activity; circles, plasma cortisol.
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renal CT showed neither adrenal adenoma nor adrenal hyper-
plasia. On the basis of her family history, strongly suggesting fa-
milial hyperaldosteronism, we prescribed 2-mg dexamethasone 
for 2 days to the patient. As expected, dexamethasone treatment 
induced a significant decline in the PAC, from 84.7 ng/dL to 12.8 
ng/dL (Fig. 2B). Taken together, we concluded that the most 
probable diagnosis is glucocorticoid-remediable hyperaldoste-
ronism. 
  We decided to study her family to identify the chimeric gene. 
The proband’s younger brother had higher blood pressure (204/ 
116 mmHg) than her. His PAC was 42.2 ng/dL, PRA was 0.03 ng/ 
mL/h, PAC/PRA ratio was 1407, sodium was 142 mEq/L, and 
potassium was 3.6 mEq/L; the liver parameters, blood cell counts, 
and renal parameters were normal. After normal saline loading, 
the PAC was not sufficiently suppressed although it decreased 
from 42.2 ng/dL to 24.2 ng/dL (Fig. 2C). Contrast-enhanced ab-
dominal CT showed normal adrenal glands. After the dexameth-
asone suppression test, his PAC dramatically declined from 38.5 
ng/dL to 1.1 ng/dL (Fig. 2D). Her father’s blood pressure has been 
controlled in the range of 140/90 mmHg with antihypertensive 
medication prescribed by a local clinic since the diagnosis of 
cerebral hemorrhage at the age of 29.
  After obtaining written informed consents from her family, 
we conducted the genetic analyses. However, because her moth-
er and younger sister did not agree to this genetic analysis, we 
could not conduct it in these family members. Genomic DNA 
was extracted from anticoagulated blood specimens by using 
the QIAamp DNA Blood Mini Kit (Qiagen, Inc., Valencia, CA, 
USA). PCR for detecting the chimeric gene was performed by 
using a previously described method (5). DNA from the subjects 
produced a 4.0-kb PCR product when amplified with a pair of 
primers specific for CYP11B2. The CYP11B2 amplification for 
each individual served as a control for the integrity of each DNA 
sample. However, DNA from the subjects produced a 3.9-kb frag-
ment when we used the sense primer for CYP11B1 and antisense 
primer for intron 5 of CYP11B2 during amplification (Fig. 3). 
After documenting chimeric gene CYP11B1/CYP11B2, we de-
cided to perform sequence analysis of the chimeric PCR prod-
uct to investigate the exact site of crossover between CYP11B1 
and CYP11B2. As shown in Fig. 4, the breakpoint of unequal cross-
ing-over was observed between intron 2 and exon 3 of the chi-
meric gene. 
  Following the diagnosis of GRA, magnetic resonance angiog-
raphy (MRA) for detecting intracranial aneurysms was perform-
ed but showed no significant findings in the proband or her 
brother. Although her father’s MRA result showed cystic enceph-
alomalacia in the left basal ganglia and old infarctions in the left 
thalamus, left cerebellum, right basal ganglia, and right parietal 
lobe, presenting the sequelae of intracranial hemorrhage, he 
too had no intracranial aneurysm (data not shown). 
  The proband was prescribed 5-mg prednisolone daily. One 
month later, her blood pressure reduced to a normal level of 
134/88 mmHg. Her brother was also prescribed 5-mg prednis-
olone daily, but his blood pressure did not show a marked de-
crease (from 170/108 mmHg to 164/86 mmHg). Therefore, we 
included spironolactone (50 mg) and lacidipine (4 mg) to his 
treatment regime. 
DISCUSSION
Primary aldosteronism occurs in at least 5–9.5% of the cases of 
essential hypertension (4, 6), and the prevalence of GRA is thought 
to account for only 0.5–1.0% of the cases of primary aldosteron-
ism (7). Actually, GRA is now considered to be the most com-
mon monogenic form of human hypertension (8). However, al-
though there are many reports of patients with primary aldo-
steronism, we believe that this is the first report of a family with 
GRA in Korea. 
  GRA, also known as familial hyperaldosteronism type I, is an 
autosomal-dominant form of low-renin hypertension charac-
terized by early onset of moderate-to-severe hypertension and 
a high incidence of premature cerebrovascular events (1). Pa-
tients with GRA show excessive production of aldosterone in 
their adrenal glands following ACTH stimulation and produce 
18-oxygenated cortisols such as 18-hydroxycortisol and 18-oxo-
cortisol, called hybrid steroids (3). 
Control
Aldosterone synthase Chimeric gene M
Control
Younger brother
Younger brother
Proband
Proband
Father
Father
Fig. 3. PCR analysis of DNA extracted from peripheral blood leukocytes of family 
members. Each subject was represented on the agarose gel. The left and right panels 
show aldosterone synthase and chimeric gene amplification, respectively. 
CYP11B1
18 bp 83 bp
Intron 2 Exon 3
214 bp
CYP11B2
Chimeric gene
Fig. 4. The breakpoints of “unequal crossing­over” by 
direct sequencing of PCR product. Nucleotide positions 
1507 and 1508 of chimeric gene were identical to intron 
2 of specific regions of CYP11B1. Nucleotide positions 
46, 61 and 64 of chimeric gene exon 3 were identical 
with specific regions of CYP11B2. Each bold charac­
teristic on nucleotide sequence of CYP11B1 or CYP11B2 
is identical to corresponding nucleotide sequence of 
chimeric gene CYP11B1/CYP11B2. Lee IS, et al.  •  Genetic Analyses of GRA 
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  Although random screening of hypertensive individuals is 
ineffective for diagnosing GRA (9), hypertensive individuals with 
a strong family history of hypertension, especially those with a 
family history of cerebral hemorrhage, early onset hypertension, 
and multidrug-resistant hypertension, should be actively screen-
ed for GRA (8). For confirming primary hyperaldosteronism in 
patients suspected to have GRA, the dexamethasone suppres-
sion test is recommended as the next diagnostic step: an aldo-
sterone level below 4 ng/dL strongly suggests GRA with high 
sensitivity (92%) and specificity (100%) (10). However, only 20% 
of the patients with dexamethasone-suppressible aldosteronism 
have chimeric gene CYP11B1/CYP11B2 (4). Therefore, a confir-
matory diagnosis of GRA is possible only with genetic tests show-
ing the chimeric gene. 
  Some authors have suggested that the crossover points of the 
chimeric gene differ between unrelated GRA families and that 
this difference affects the severity of hypertension (11). In our 
case, the crossover point was between intron 2 of CYP11B1 and 
exon 3 of CYP11B2. Although sequencing analysis of only one 
family with GRA cannot explain the role of the crossover points 
in the clinical severity, on the basis of a literature review (12), we 
consider that our sequencing analysis provides evidence sug-
gesting that the proportion of CYP11B2 in the chimeric gene is 
responsible for inducing excessive aldosterone synthesis. Inter-
estingly, the proband showed relatively lower blood pressure 
than her younger brother, and the hypertension was easily con-
trollable with prednisolone. Actually, the phenotypic features of 
GRA can be diverse even within families and may be determined 
by various factors such as the proportion of CYP11B2 in the chi-
meric gene, sex, and other genetic traits such as mineralocorti-
coid receptor or sodium epithelial channel defects (13, 14). Tak-
en together, the proband might be relatively protected by ovari-
an steroids or the genetic traits (15).
  Administration of low-dose glucocorticoids such as prednis-
olone, suppressing pituitary ACTH secretion, is the treatment 
of choice for patients with GRA. The steroid dosage should be 
titrated against the blood pressure and maintained as low as 
possible to achieve adequate control. Individualized dosage ti-
tration does not result in normalization of biochemical markers 
such as urinary 18-oxosteroid or serum aldosterone levels, be-
cause these remain elevated in the majority of the patients with 
GRA whose blood pressure normalizes (15). If prednisolone does 
not effectively reduce the blood pressure, such as in the case of 
our proband’s younger brother, type I mineralocorticoid recep-
tor antagonists such as eplerenone and spironolactone or sodi-
um epithelial channel antagonists such as amiloride and triam-
terene could be used successfully (16). However, nondirected 
antihypertensives such as β-blockers and angiotensin-convert-
ing enzyme inhibitors are less likely to be effective (17). 
  In summary, we have reported three cases of GRA in a Korean 
family, confirmed by genetic analyses. Although the dexameth-
asone suppression test is useful for diagnosis, detection of the 
chimeric gene is important for confirmatory diagnosis of GRA, 
for which PCR seems to be highly reliable. Therefore, hyperten-
sive individuals with a strong family history of hypertension, es-
pecially those with a family history of cerebral hemorrhage, ear-
ly onset hypertension, and multidrug-resistant hypertension, 
should be actively screened. If GRA is suspected, rigorous ge-
netic analyses should be performed. These vigorous efforts to 
investigate the genetic traits of GRA family would make it possi-
ble to create guideline for GRA screening in Korea.
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